Q3 2024 Perimeter Medical Imaging AI Inc Earnings Call Transcript
Key Points
- Perimeter Medical Imaging AI Inc (PYNKF) has successfully completed patient enrollment in a pivotal clinical trial for its B SERIES OCT with Image Assist AI, which could be a significant catalyst for the company.
- The company has seen positive commercial traction with its S SERIES OCT, with 14 devices currently in commercial use in the US.
- Perimeter Medical Imaging AI Inc (PYNKF) is pioneering the integration of AI in breast cancer surgical devices, potentially reducing the learning curve for surgeons and expanding its customer base.
- The company anticipates releasing top-line data from the pivotal trial soon, which could support a submission to the FDA for market authorization in 2025.
- Perimeter Medical Imaging AI Inc (PYNKF) has a strong financial position with approximately $9.5 million in cash and cash equivalents as of September 30, 2024, not including additional funds from recent financing activities.
- The company reported a net loss of approximately $4.6 million for Q3 2024, a significant increase from the $345,000 loss in the same period in 2023.
- Operating expenses remained high at approximately $4.5 million for the third quarter, unchanged from the previous year.
- The increase in net loss was primarily due to non-cash expenses related to the revaluation of warrant liability and net foreign exchange loss.
- There is uncertainty regarding the exact timing of FDA authorization for the B SERIES OCT, which could impact the company's go-to-market strategy.
- The current S SERIES OCT is tissue agnostic and lacks specific claims for breast cancer and margin reduction, limiting its marketing potential in the breast cancer space.
Good afternoon. Ladies and gentlemen and welcome to the Perimeter Medical Q3 2024 conference call. (Operator Instructions) This call is being recorded on Thursday, November 14, 2024.
And I would now like to turn the conference over to Stephen Kilmer investor relations. Please go ahead.
Thank you. Good afternoon. Everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities. Plus, these may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes. The potential benefits of our products including perimeter S series oct, perimeter BB series oct and perimeter image assist perimeter ability to broaden its user base and the expected approval of its proprietary A I expectations regarding new
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
